Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification

Abstract Background An important mechanism that promoter methylation-mediated gene silencing for inactivation is identified in human tumorigenesis. Methylated genes have been found breast cancer (BC) and beneficial biomarkers early diagnosis. Prognostic assessment of remain little known. Zinc finger protein 132 (ZNF132) downregulated by methylation prostate esophageal squamous cell carcinoma. However, no study provides information on the status ZNF132, analyzes diagnosis prognostic significance ZNF132 BC. Methods In present study, expression mRNA level was determined based Cancer Genome Atlas (TCGA) RNA-Seq database clinical samples analysis multiple lines verification. P rognostic BC assessed using Kaplan-Meier plotter. Molecular mechanisms exploration performed bioinformatic tools. Hypermethylated confirmed via Methylation specific polymerase chain reaction (MSP) analysis. Results The both levels tissues. These results were obtained TCGA sample Survival from plotter revealed lower associated with a shorter Relapse Free (RFS) time. Receiver operating characteristic curve (ROC) 0.887 had powerful sensitivity specificity to distinguish between adjacent normal Bioinformatic showed 6% ((58/960)) alterations cBioPortal. participated biological pathways Gene Set Enrichment Analysis (GSEA) including regulation cycle glycolysis. Finally, MSP demonstrated hypermethylated panel 5-aza-2′-deoxycytidine (5-Aza-dC) treatment restored partial lines. Conclusions hypermethylation contributed its could be as new diagnostic marker